Jak inhibitor; Possibility and mechanism as a new disease modifying anti-rheumatic drug

Kunihiro Yamaoka, Yoshiya Tanaka

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Treatment of rheumatoid arthritis (RA) has developed dramatically by the appearance of biologics. However the development of a new anti-rheumatic drug is necessary because of its issue on route of administration and expense. Recently, inhibitors targeting tyrosine kinase known as Janus kinase (Jak) has shown prominent effect on RA. Jak family is comprised by Jakl, Jak2, Jak3 and Tyk2 which is necessary for signal transduction for inflammatory cytokines. INCB18424 targeting Jak1/2 and CP690,550 targeting Jak3 has been developed and is now on phase II clinical study for RA. Results from those clinical studies have proven that these inhibitors can be effective as biologics with few side effects. However, it has been reported that inhibitors are less specific than it has been expect and that non-specificity can be important for its effect. Therefore, we think that the mechanism of inhibitors cannot be explained by its inhibition of a single kinase. Herein, we describe IL-10 overproduction by Jak3 and Stat6 deficient dendritic cell. We speculate that this is one possible mechanism of action for CP690,550 although as for its non-specificity we need further investigation to predict not only its effect but also its side effect in a long term administration.

Original languageEnglish
Pages (from-to)85-91
Number of pages7
JournalJapanese Journal of Clinical Immunology
Volume32
Issue number2
DOIs
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

Janus Kinases
Antirheumatic Agents
Rheumatoid Arthritis
Biological Products
Interleukin-10
Protein-Tyrosine Kinases
Dendritic Cells
Signal Transduction
Phosphotransferases
Cytokines
Clinical Studies

Keywords

  • Jak inhibitor
  • Rheumatoid arthritis
  • Specificity

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Jak inhibitor; Possibility and mechanism as a new disease modifying anti-rheumatic drug. / Yamaoka, Kunihiro; Tanaka, Yoshiya.

In: Japanese Journal of Clinical Immunology, Vol. 32, No. 2, 2009, p. 85-91.

Research output: Contribution to journalArticle

@article{43a50014f3664349848c2a7d060ad72a,
title = "Jak inhibitor; Possibility and mechanism as a new disease modifying anti-rheumatic drug",
abstract = "Treatment of rheumatoid arthritis (RA) has developed dramatically by the appearance of biologics. However the development of a new anti-rheumatic drug is necessary because of its issue on route of administration and expense. Recently, inhibitors targeting tyrosine kinase known as Janus kinase (Jak) has shown prominent effect on RA. Jak family is comprised by Jakl, Jak2, Jak3 and Tyk2 which is necessary for signal transduction for inflammatory cytokines. INCB18424 targeting Jak1/2 and CP690,550 targeting Jak3 has been developed and is now on phase II clinical study for RA. Results from those clinical studies have proven that these inhibitors can be effective as biologics with few side effects. However, it has been reported that inhibitors are less specific than it has been expect and that non-specificity can be important for its effect. Therefore, we think that the mechanism of inhibitors cannot be explained by its inhibition of a single kinase. Herein, we describe IL-10 overproduction by Jak3 and Stat6 deficient dendritic cell. We speculate that this is one possible mechanism of action for CP690,550 although as for its non-specificity we need further investigation to predict not only its effect but also its side effect in a long term administration.",
keywords = "Jak inhibitor, Rheumatoid arthritis, Specificity",
author = "Kunihiro Yamaoka and Yoshiya Tanaka",
year = "2009",
doi = "10.2177/jsci.32.85",
language = "English",
volume = "32",
pages = "85--91",
journal = "Immunological Medicine",
issn = "0911-4300",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Jak inhibitor; Possibility and mechanism as a new disease modifying anti-rheumatic drug

AU - Yamaoka, Kunihiro

AU - Tanaka, Yoshiya

PY - 2009

Y1 - 2009

N2 - Treatment of rheumatoid arthritis (RA) has developed dramatically by the appearance of biologics. However the development of a new anti-rheumatic drug is necessary because of its issue on route of administration and expense. Recently, inhibitors targeting tyrosine kinase known as Janus kinase (Jak) has shown prominent effect on RA. Jak family is comprised by Jakl, Jak2, Jak3 and Tyk2 which is necessary for signal transduction for inflammatory cytokines. INCB18424 targeting Jak1/2 and CP690,550 targeting Jak3 has been developed and is now on phase II clinical study for RA. Results from those clinical studies have proven that these inhibitors can be effective as biologics with few side effects. However, it has been reported that inhibitors are less specific than it has been expect and that non-specificity can be important for its effect. Therefore, we think that the mechanism of inhibitors cannot be explained by its inhibition of a single kinase. Herein, we describe IL-10 overproduction by Jak3 and Stat6 deficient dendritic cell. We speculate that this is one possible mechanism of action for CP690,550 although as for its non-specificity we need further investigation to predict not only its effect but also its side effect in a long term administration.

AB - Treatment of rheumatoid arthritis (RA) has developed dramatically by the appearance of biologics. However the development of a new anti-rheumatic drug is necessary because of its issue on route of administration and expense. Recently, inhibitors targeting tyrosine kinase known as Janus kinase (Jak) has shown prominent effect on RA. Jak family is comprised by Jakl, Jak2, Jak3 and Tyk2 which is necessary for signal transduction for inflammatory cytokines. INCB18424 targeting Jak1/2 and CP690,550 targeting Jak3 has been developed and is now on phase II clinical study for RA. Results from those clinical studies have proven that these inhibitors can be effective as biologics with few side effects. However, it has been reported that inhibitors are less specific than it has been expect and that non-specificity can be important for its effect. Therefore, we think that the mechanism of inhibitors cannot be explained by its inhibition of a single kinase. Herein, we describe IL-10 overproduction by Jak3 and Stat6 deficient dendritic cell. We speculate that this is one possible mechanism of action for CP690,550 although as for its non-specificity we need further investigation to predict not only its effect but also its side effect in a long term administration.

KW - Jak inhibitor

KW - Rheumatoid arthritis

KW - Specificity

UR - http://www.scopus.com/inward/record.url?scp=77953673416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953673416&partnerID=8YFLogxK

U2 - 10.2177/jsci.32.85

DO - 10.2177/jsci.32.85

M3 - Article

VL - 32

SP - 85

EP - 91

JO - Immunological Medicine

JF - Immunological Medicine

SN - 0911-4300

IS - 2

ER -